For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.
Scope of the Report:
This report focuses on the EGFR Mutation Test in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period.
The worldwide market for EGFR Mutation Test is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
-Thermo Fisher Scientific
Market Segment by Regions, regional analysis covers
-North America (United States, Canada and Mexico)
-Europe (Germany, France, UK, Russia and Italy)
-Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
-South America (Brazil, Argentina, Colombia etc.)
-Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
-Clinical Research Institutes
There are 15 Chapters to deeply display the global EGFR Mutation Test market.
Chapter 1, to describe EGFR Mutation Test Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of EGFR Mutation Test, with sales, revenue, and price of EGFR Mutation Test, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of EGFR Mutation Test, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, EGFR Mutation Test market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe EGFR Mutation Test sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source